Literature DB >> 22162117

Do patients with type 2 diabetes mellitus have an increased prevalence of Cushing's syndrome?

Therese Krarup1, Thure Krarup, Claus Hagen.   

Abstract

Many clinical features are common for patients with type 2 diabetes mellitus (T2DM) and Cushing's syndrome (CS) such as central obesity, hypertension and dyslipidaemia. Patients with CS often have T2DM. Because T2DM is much more frequent than CS, it is possible that some patients with T2DM have increased production of cortisol and thus represent patients with CS. The aim of this review was to evaluate the prevalence of CS in patients with T2DM. A search was performed in PubMed and Medline. We found seven prospective studies, two case-control studies and two cross-sectional studies. The difficulties in diagnosing subclinical CS is discussed. The most frequent tests for diagnosing CS, late-night salivary cortisol, 1-mg dexamethasone suppression test and urinary free cortisol are discussed and put in relation to the results of the literature found. The observed prevalence of CS in patients with T2DM varies widely between the different studies, ranging from 0-9.4%. This may be due to patient selection, differences in test methodology (including choice of test), cutoff values and different cortisol assays. The true prevalence of CS in T2DM has not been determined. We need more studies investigating the prevalence of CS in T2DM patients. There is a need for developing more specific tests for diagnosing CS in patients with only slightly elevated cortisol secretion and subclinical CS. We suggest that examination for hypercortisolism should only be performed in T2DM patients with a cushingoid appearance and hypertension or truncal obesity or dyslipidaemia.
Copyright © 2011 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22162117     DOI: 10.1002/dmrr.2262

Source DB:  PubMed          Journal:  Diabetes Metab Res Rev        ISSN: 1520-7552            Impact factor:   4.876


  7 in total

1.  Is the hypothalamic-pituitary-adrenal axis disrupted in type 2 diabetes mellitus?

Authors:  Hershel Raff; Steven B Magill
Journal:  Endocrine       Date:  2016-09-30       Impact factor: 3.633

2.  Serum but not salivary cortisol levels are influenced by daily glycemic oscillations in type 2 diabetes.

Authors:  Giuseppe Bellastella; Maria Ida Maiorino; Annamaria De Bellis; Maria Teresa Vietri; Carmela Mosca; Lorenzo Scappaticcio; Daniela Pasquali; Katherine Esposito; Dario Giugliano
Journal:  Endocrine       Date:  2015-10-28       Impact factor: 3.633

Review 3.  A systematic review and meta-analysis of the impact of mineralocorticoid receptor antagonists on glucose homeostasis.

Authors:  Sandra Korol; Fannie Mottet; Sylvie Perreault; William L Baker; Michel White; Simon de Denus
Journal:  Medicine (Baltimore)       Date:  2017-12       Impact factor: 1.817

4.  Mitigation of MAFLD in High Fat-High Sucrose-Fructose Fed Mice by a Combination of Genistein Consumption and Exercise Training.

Authors:  Chaheyla R St Aubin; Amy L Fisher; Jose A Hernandez; Tom L Broderick; Layla Al-Nakkash
Journal:  Diabetes Metab Syndr Obes       Date:  2022-07-23       Impact factor: 3.249

Review 5.  Disorders of the adrenal cortex: Genetic and molecular aspects.

Authors:  Georgia Pitsava; Andrea G Maria; Fabio R Faucz
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-29       Impact factor: 6.055

6.  Routine Screening for Cushing's Syndrome Is Not Required in Patients Presenting with Obesity.

Authors:  Serap Baydur Sahin; Hacer Sezgin; Teslime Ayaz; Emine Uslu Gur; Kadir Ilkkilic
Journal:  ISRN Endocrinol       Date:  2013-06-11

7.  Glucocorticoids and type 2 diabetes: from physiology to pathology.

Authors:  Guido Di Dalmazi; Uberto Pagotto; Renato Pasquali; Valentina Vicennati
Journal:  J Nutr Metab       Date:  2012-12-18
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.